Risk factor
Limited trading liquidity
Profitability factor
Favourable analyst view
About
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of SHILPAMED.NS is 541 and suggests 61% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell